IP Library › Granted Patent US 12,421,498
Granted Patent B2
US 12,421,498 · App. 16/768,203 · Granted Sep 23, 2025

Ectodermal mesenchymal stem cells and method for producing same

Inventors: Katsuto Tamai (Suita, JP); Takashi Shimbo (Suita, JP); Eiji Sasaki (Suita, JP); Takehiko Yamazaki (Toyonaka, JP)
Assignees: STEMRIM INC.; OSAKA UNIVERSITY
C12N5/0663A61K35/28C07K14/47G01N33/5073A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,421,498
App. No.
16/768,203
Granted
Sep 23, 2025
Kind
B2
Abstract

The inventors discovered that ectodermal mesenchymal stem cells circulating in peripheral blood that are induced by necrotic tissue damage contribute to the regeneration of damaged tissue. On the basis of this discovery, provided are ectodermal mesenchymal stem cells, a method for producing the same, and a screening method for a substance having pluripotent stem cell inductive activity, the screening method using cells induced by necrotic tissue damage in peripheral blood as an index.

Claims (48)

1. A method for producing an ectomesenchymal stem cell or a cell population containing the ectomesenchymal stem cell, comprising any one of steps 1) to 9) below:

1) collecting peripheral blood from a subject having a necrotic tissue injury, culturing the peripheral blood to obtain a colony-forming cell, and then selectively recovering a cell that is PDGFRα-positive and Prx1 lineage-negative, wherein the subject is a transgenic animal selected from the group consisting of mouse, rat, monkey, pig, dog, rabbit, hamster, guinea pig, horse, and sheep;

2) collecting peripheral blood from a subject having a necrotic tissue injury, and selectively recovering a cell that is PDGFRα-positive and Prx1 lineage-negative from the peripheral blood, wherein the subject is a transgenic animal selected from the group consisting of mouse, rat, monkey, pig, dog, rabbit, hamster, guinea pig, horse, and sheep;

3) collecting peripheral blood from a subject having a necrotic tissue injury, and selectively recovering a cell that is PDGFRα-positive, CD34-positive and Sca1-negative from the peripheral blood, wherein the subject is selected from the group consisting of mouse, rat, and hamster;

4) collecting peripheral blood from a subject having a necrotic tissue injury, and selectively recovering a cell that is PDGFRα-positive, Prx1 lineage-negative, CD34-positive and Sca1-negative from the peripheral blood, wherein the subject is a transgenic animal selected from the group consisting of mouse, rat, and hamster;

5) collecting peripheral blood from a subject having a necrotic tissue injury, and selectively recovering a cell that is PDGFRα-positive and CD34-positive from the peripheral blood, wherein the subject is selected from the group consisting of human, mouse, rat, monkey, pig, dog, rabbit, hamster, guinea pig, horse, and sheep;

6) collecting peripheral blood from a subject having a necrotic tissue injury, selectively recovering a cell that is PDGFRα-positive and Prx1 lineage-negative from the peripheral blood, and culturing the cell to obtain a colony-forming cell, wherein the subject is a transgenic animal selected from the group consisting of mouse, rat, monkey, pig, dog, rabbit, hamster, guinea pig, horse, and sheep;

7) collecting peripheral blood from a subject having a necrotic tissue injury, selectively recovering a cell that is PDGFRα-positive, CD34-positive and Sca1-negative from the peripheral blood, and culturing the cell to obtain a colony-forming cell, wherein the subject is selected from the group consisting of mouse, rat, and hamster;

8) collecting peripheral blood from a subject having a necrotic tissue injury, selectively recovering a cell that is PDGFRα-positive, Prx1 lineage-negative, CD34-positive and Sca1-negative from the peripheral blood, and culturing the cell to obtain a colony-forming cell, wherein the subject is a transgenic animal selected from the group consisting of mouse, rat, and hamster; or

9) collecting peripheral blood from a subject having a necrotic tissue injury, selectively recovering a cell that is PDGFRα-positive and CD34-positive from the peripheral blood, and culturing the cell to obtain a colony-forming cell, wherein the subject is selected from the group consisting of human, mouse, rat, monkey, pig, dog, rabbit, hamster, guinea pig, horse, and sheep.

2. A method for producing an ectomesenchymal stem cell, comprising any one of steps 1) to 6) below:

1) collecting a vertebral bone marrow from a subject, culturing the vertebral bone marrow to obtain a colony-forming cell, and then selectively recovering a cell that is PDGFRα-positive, CD34-positive and Sca1-negative, wherein the subject is selected from the group consisting of mouse, rat, and hamster;

2) collecting a vertebral bone marrow from a subject, culturing the vertebral bone marrow to obtain a colony-forming cell, and then selectively recovering a cell that is PDGFRα-positive and CD34-positive, wherein the subject is selected from the group consisting of human, mouse, rat, monkey, pig, dog, rabbit, hamster, guinea pig, horse, and sheep;

3) collecting a vertebral bone marrow from a subject, and selectively recovering a cell that is PDGFRα-positive, CD34-positive and Sca1-negative from the vertebral bone marrow, wherein the subject is selected from the group consisting of mouse, rat, and hamster;

4) collecting a vertebral bone marrow from a subject, and selectively recovering a cell that is PDGFRα-positive and CD34-positive from the vertebral bone marrow, wherein the subject is selected from the group consisting of human, mouse, rat, monkey, pig, dog, rabbit, hamster, guinea pig, horse, and sheep;

5) collecting a vertebral bone marrow from a subject, selectively recovering a cell that is PDGFRα-positive, CD34-positive and Sca1-negative from the vertebral bone marrow, and culturing the cell to obtain a colony-forming cell, wherein the subject is selected from the group consisting of mouse, rat, and hamster; or

6) collecting a vertebral bone marrow from a subject, selectively recovering a cell that is PDGFRα-positive and CD34-positive from the vertebral bone marrow, and culturing the cell to obtain a colony-forming cell, wherein the subject is selected from the group consisting of human, mouse, rat, monkey, pig, dog, rabbit, hamster, guinea pig, horse, and sheep.

3. A method for producing an ectomesenchymal stem cell, comprising:

1) the steps of culturing a cell population derived from a biological tissue of a subject to obtain a colony-forming cell, and then selecting a colony that is PDGFRα-positive and Prx1 lineage-negative,

wherein the biological tissue is peripheral blood or a bone marrow of femur, vertebra, sternum or ilium, the subject is a transgenic animal selected from the group consisting of mouse, rat, monkey, pig, dog, rabbit, hamster, guinea pig, horse and sheep, and the selected colony comprises ectomesenchymal stem cell; or

2) the steps of culturing a cell population derived from a biological tissue of a subject to obtain a colony-forming cell, and then selecting a colony that is PDGFRα-positive, Prx1 lineage-negative, CD34-positive and Sca1-negative,

wherein the biological tissue is peripheral blood or a bone marrow of femur, vertebra, sternum or ilium, the subject is a transgenic animal selected from the group consisting of mouse, rat, and hamster, and the selected colony comprises ectomesenchymal stem cell.

4. A method for producing a cell population containing an ectomesenchymal stem cell, comprising a step of:

1) selectively recovering a cell that is PDGFRα-positive and Prx1 lineage-negative from a cell population derived from a biological tissue of a subject, wherein the biological tissue is peripheral blood or a bone marrow of femur, vertebra, sternum or ilium, the subject is a transgenic animal selected from the group consisting of mouse, rat, monkey, pig, dog, rabbit, hamster, guinea pig, horse and sheep, and the selectively recovered cell comprises ectomesenchymal stem cell; or

2) selectively recovering a cell that is PDGFRα-positive, Prx1 lineage-negative, CD34-positive and Sca1-negative from a cell population derived from a biological tissue of a subject, wherein the biological tissue is peripheral blood or a bone marrow of femur, vertebra, sternum or ilium, the subject is a transgenic animal selected from the group consisting of mouse, rat, and hamster, and the selectively recovered cell comprises ectomesenchymal stem cell.

5. A method for producing an ectomesenchymal stem cell, comprising:

1) the steps of selectively recovering a cell that is PDGFRα-positive and Prx1 lineage-negative from a cell population derived from a biological tissue of a subject, and culturing the selectively recovered cell to obtain a colony-forming cell,

wherein the biological tissue is peripheral blood or a bone marrow of femur, vertebra, sternum or ilium, the subject is a transgenic animal selected from the group consisting of mouse, rat, monkey, pig, dog, rabbit, hamster, guinea pig, horse and sheep, and the colony-forming cell comprises ectomesenchymal stem cell; or

2) the steps of selectively recovering a cell that is PDGFRα-positive, Prx1 lineage-negative, CD34-positive and Sca1-negative from a cell population derived from a biological tissue of a subject, and culturing the selectively recovered cell to obtain a colony-forming cell,

wherein the biological tissue is peripheral blood or a bone marrow of femur, vertebra, sternum or ilium, the subject is a transgenic animal selected from the group consisting of mouse, rat, and hamster, and the colony-forming cell comprises ectomesenchymal stem cell.

6. A method for producing an ectomesenchymal stem cell, comprising:

1) the steps of collecting a vertebral bone marrow from a subject and selectively recovering a cell having any one of characteristics (a) and (b) below from the vertebral bone marrow:

(a) being PDGFRα-positive, CD34-positive, and Sca1-negative;

(b) being PDGFRα-positive, CD34-positive, and Sca1-positive,

wherein the subject is selected from the group consisting of mouse, rat, and hamster; or

2) the steps of collecting a vertebral bone marrow from a subject and selectively recovering a cell that is PDGFRα-positive and CD34-positive from the vertebral bone marrow,

wherein the subject is selected from the group consisting of human, mouse, rat, monkey, pig, dog, rabbit, hamster, guinea pig, horse, and sheep.

7. A method for producing an ectomesenchymal stem cell, comprising:

1) the steps of collecting a vertebral bone marrow from a subject and selectively recovering a cell having any one of characteristics (a) and (b) below from the vertebral bone marrow:

(a) being PDGFRα-positive and Procr-positive;

(b) being PDGFRα-positive, Procr-positive and CD34-positive,

wherein the subject is selected from the group consisting of human, mouse, rat, monkey, pig, dog, rabbit, hamster, guinea pig, horse, and sheep; or

2) the steps of collecting a vertebral bone marrow from a subject and selectively recovering a cell having any one of characteristics (c) and (d) below from the vertebral bone marrow:

(c) being PDGFRα-positive, Procr-positive and Sca1-positive;

(d) being PDGFRα-positive, Procr-positive, CD34-positive and Sca1-positive,

wherein the subject is selected from the group consisting of mouse, rat, and hamster.

8. The method of claim 1 , further comprising a step of removing red blood cells prior to the culturing step of step 1), 6), 7), 8) or 9).

9. The method of claim 2 , further comprising a step of removing red blood cells prior to the culturing step of step 1), 2), 5) or 6).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2020
From: TAMAI, KATSUTO; SHIMBO, TAKASHI; SASAKI, EIJI; YAMAZAKI, TAKEHIKO
To: STEMRIM INC.; OSAKA UNIVERSITY
Reel/Frame 052787/0001 →
Continuity (2)
Provisional Application 62593310 · Dec 1, 2017
Related Publication 20200291359A1 · Sep 17, 2020
References Cited (400)
US 3896810A · Akiyama · 1975 [cited by applicant]
US 4732155A · Zetter et al. · 1988 [cited by applicant]
US 5133755A · Brekke · 1992 [cited by applicant]
US 5661127A · Bhatnagar et al. · 1997 [cited by applicant]
US 5760261A · Guttag · 1998 [cited by applicant]
US 5851986A · Takada et al. · 1998 [cited by applicant]
US 5902799A · Herrmann et al. · 1999 [cited by applicant]
US 6586185B2 · Wolf et al. · 2003 [cited by applicant]
US 6905874B2 · Berenson et al. · 2005 [cited by applicant]
US 7160904B2 · Cooke et al. · 2007 [cited by applicant]
US 7220723B2 · Tracey et al. · 2007 [cited by applicant]
US 7288250B2 · Newman et al. · 2007 [cited by applicant]
US 7446100B2 · Pilarski · 2008 [cited by applicant]
US 7470538B2 · Laughlin et al. · 2008 [cited by applicant]
US 7632802B2 · Tessier et al. · 2009 [cited by applicant]
US 7749959B2 · Tracey et al. · 2010 [cited by applicant]
US 7754217B2 · Bianchi et al. · 2010 [cited by applicant]
US 7833975B2 · Okazawa · 2010 [cited by applicant]
US 7939057B2 · Battista et al. · 2011 [cited by applicant]
US 8119121B2 · Fraser et al. · 2012 [cited by applicant]
US 8546547B2 · Traversa et al. · 2013 [cited by applicant]
US 8551470B2 · Son et al. · 2013 [cited by applicant]
US 9623078B2 · Tamai et al. · 2017 [cited by applicant]
US 9688733B2 · Tamai et al. · 2017 [cited by applicant]
US 9707298B2 · Traversa et al. · 2017 [cited by applicant]
US 10364276B2 · Tamai et al. · 2019 [cited by applicant]
US 10393762B2 · Fuhrmann et al. · 2019 [cited by applicant]
US 10550165B2 · Tamai et al. · 2020 [cited by applicant]
US 10595530B2 · Goodman et al. · 2020 [cited by applicant]
US 10626153B2 · Bianchi et al. · 2020 [cited by applicant]
US 11298403B2 · Tamai et al. · 2022 [cited by applicant]
US 20030003482A1 · Halle et al. · 2003 [cited by applicant]
US 20030060410A1 · Tracey et al. · 2003 [cited by applicant]
US 20040031072A1 · La Rosa et al. · 2004 [cited by applicant]
US 20040053841A1 · Tracey et al. · 2004 [cited by applicant]
US 20040156851A1 · Newman · 2004 [cited by applicant]
US 20040191246A1 · Connelly et al. · 2004 [cited by applicant]
US 20040242481A1 · Bianchi et al. · 2004 [cited by applicant]
US 20040249448A1 · Gault · 2004 [cited by applicant]
US 20040265971A1 · Sato et al. · 2004 [cited by applicant]
US 20050014255A1 · Tang et al. · 2005 [cited by applicant]
US 20050101564A1 · Pilarski · 2005 [cited by applicant]
US 20080038309A1 · Fumero et al. · 2008 [cited by applicant]
US 20090028832A1 · Chung et al. · 2009 [cited by applicant]
US 20090053277A1 · Nagaya et al. · 2009 [cited by applicant]
US 20090105341A1 · Stanton · 2009 [cited by applicant]
US 20090324677A1 · Traversa et al. · 2009 [cited by applicant]
US 20100040608A1 · Wahren-Herlenius et al. · 2010 [cited by applicant]
US 20120178676A1 · Barrack et al. · 2012 [cited by applicant]
US 20120237504A1 · Brooks et al. · 2012 [cited by applicant]
US 20140065094A1 · Traversa et al. · 2014 [cited by applicant]
US 20140206619A1 · Tamai et al. · 2014 [cited by applicant]
US 20150273017A1 · Tamai et al. · 2015 [cited by applicant]
US 20150274792A1 · Tamai et al. · 2015 [cited by applicant]
US 20160032248A1 · Short et al. · 2016 [cited by applicant]
US 20170304398A1 · Traversa et al. · 2017 [cited by applicant]
US 20180055886A1 · Tamai et al. · 2018 [cited by applicant]
US 20180072785A1 · Tamai et al. · 2018 [cited by applicant]
US 20190343924A1 · Tamai et al. · 2019 [cited by applicant]
US 20200038486A1 · Tamai et al. · 2020 [cited by applicant]
US 20200291359A1 · Tamai et al. · 2020 [cited by applicant]
US 20200369736A1 · Tamai et al. · 2020 [cited by applicant]
US 20210024594A1 · Tamai et al. · 2021 [cited by applicant]
US 20210163552A1 · Nihashi et al. · 2021 [cited by applicant]
US 20210347839A1 · Tamai et al. · 2021 [cited by applicant]
US 20220009976A1 · Tamai et al. · 2022 [cited by applicant]
AU 2003228099 · 2004 [cited by applicant]
AU 2004203732 · 2004 [cited by applicant]
CA 2325226 · 2001 [cited by applicant]
CA 2512512 · 2004 [cited by applicant]
CA 2636788 · 2008 [cited by applicant]
CN 1516739 · 2004 [cited by applicant]
CN 1193092 · 2005 [cited by applicant]
CN 1671742 · 2005 [cited by applicant]
CN 100447154 · 2008 [cited by applicant]
CN 101366728 · 2009 [cited by applicant]
CN 101374538 · 2009 [cited by applicant]
CN 102076350 · 2011 [cited by applicant]
CN 102247392 · 2011 [cited by applicant]
CN 102443064 · 2012 [cited by applicant]
CN 102711777 · 2012 [cited by applicant]
CN 105026553 · 2015 [cited by applicant]
EP 1114862 · 2001 [cited by applicant]
EP 1459759 · 2004 [cited by applicant]
EP 0791601 · 2005 [cited by applicant]
EP 2039367 · 2009 [cited by applicant]
EP 2055308 · 2009 [cited by applicant]
EP 2284255 · 2011 [cited by applicant]
EP 2301559 · 2011 [cited by applicant]
EP 2301560 · 2011 [cited by applicant]
EP 2703487 · 2014 [cited by applicant]
EP 2913058 · 2015 [cited by applicant]
EP 3556378 · 2019 [cited by applicant]
EP 3719117 · 2020 [cited by applicant]
EP 3750553 · 2020 [cited by applicant]
JP 3018313 · 2000 [cited by applicant]
JP 2003505506 · 2003 [cited by applicant]
JP 3421741 · 2003 [cited by applicant]
JP 2005508913 · 2005 [cited by applicant]
JP 2005512507 · 2005 [cited by applicant]
JP 2005537253 · 2005 [cited by applicant]
JP 2006510619 · 2006 [cited by applicant]
JP 2006517537 · 2006 [cited by applicant]
JP 2006523085 · 2006 [cited by applicant]
JP 2007320919 · 2007 [cited by applicant]
JP 2008507505 · 2008 [cited by applicant]
JP 2008511300 · 2008 [cited by applicant]
JP 2010503630 · 2010 [cited by applicant]
JP 4982739 · 2012 [cited by applicant]
JP 5134772 · 2013 [cited by applicant]
JP 5814549 · 2015 [cited by applicant]
KR 1020090078304 · 2009 [cited by applicant]
RU 2005102593 · 2005 [cited by applicant]
RU 2410125 · 2009 [cited by applicant]
RU 2010148785 · 2012 [cited by applicant]
RU 2599448 · 2016 [cited by applicant]
WO 0108683 · 2001 [cited by applicant]
WO 02074337 · 2002 [cited by applicant]
WO 02088181 · 2002 [cited by applicant]
WO 02092004 · 2002 [cited by applicant]
WO 03026691 · 2003 [cited by applicant]
WO 03043651 · 2003 [cited by applicant]
WO 2004004763 · 2004 [cited by applicant]
WO 2004004770 · 2004 [cited by applicant]
WO 2004044001 · 2004 [cited by applicant]
WO 2004046345 · 2004 [cited by applicant]
WO 2004061456 · 2004 [cited by applicant]
WO 2005025604 · 2005 [cited by applicant]
WO 2005074984 · 2005 [cited by applicant]
WO 2005087797 · 2005 [cited by applicant]
WO 2006008779 · 2006 [cited by applicant]
WO 2006010628 · 2006 [cited by applicant]
WO 2006024547 · 2006 [cited by applicant]
WO 2006080434 · 2006 [cited by applicant]
WO 2006047820 · 2006 [cited by applicant]
WO 2006077614 · 2006 [cited by applicant]
WO 2006100651 · 2006 [cited by applicant]
WO 2006114805 · 2006 [cited by applicant]
WO 2007015546 · 2007 [cited by applicant]
WO 2007031100 · 2007 [cited by applicant]
WO 2007061762 · 2007 [cited by applicant]
WO 2007076200 · 2007 [cited by applicant]
WO 2007130725 · 2007 [cited by applicant]
WO 2008018641 · 2008 [cited by applicant]
WO 2008031612 · 2008 [cited by applicant]
WO 2008053892 · 2008 [cited by applicant]
WO 2008155659 · 2008 [cited by applicant]
WO 2009133939 · 2009 [cited by applicant]
WO 2009133940 · 2009 [cited by applicant]
WO 2009133943 · 2009 [cited by applicant]
WO 2011046570 · 2011 [cited by applicant]
WO 2011052668 · 2011 [cited by applicant]
WO 2012147470 · 2012 [cited by applicant]
WO 2014065347 · 2014 [cited by applicant]
WO 2014065348 · 2014 [cited by applicant]
WO 2014191364 · 2014 [cited by applicant]
WO 2016184795 · 2016 [cited by applicant]
WO 2018139562 · 2018 [cited by applicant]
WO 2018186480 · 2018 [cited by applicant]
WO 2018199107 · 2018 [cited by applicant]
WO 2019107530 · 2019 [cited by applicant]
WO 2019107566 · 2019 [cited by applicant]
WO 2019156137 · 2019 [cited by applicant]
WO 2020071519 · 2020 [cited by applicant]
WO 2020071520 · 2020 [cited by applicant]
Baer et al. Comprehensive Phenotypic Characterization of Human Adipose-Derived Stromal/Stem Cells and Their Subsets by a High Throughput Technology. Stem Cells and Development vol. 22, No. 2, p. 330-339 (Year: 2013). [cited by examiner]
Sidney et al. Concise Review: Evidence for CD34 as a Common Marker for Diverse Progenitors. Stem Cells 2014;32:1380-1389 (Year: 2014). [cited by examiner]
Suchacki et al. Bone marrow adipose tissue: formation, function and regulation. Curr Opin Pharmacol. Jun. 2016 ; 28: 50-56 (Year: 2016). [cited by examiner]
PROCR gene—Protein C Receptor. downloaded from https://www.genecards.org/cgi-bin/carddisp.pl?gene=PROCR (Year: 2022). [cited by examiner]
Morikawa et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J. Exp. Med. vol. 206 No. 11 2483-2496. (Year: 2009). [cited by examiner]
Ahrens et al. Mesenchymal Stem Cell Content of Human Vertebral Bone Marrow. Transplantation ⋅ vol. 78, No. 6, p. 925-929 (Year: 2004). [cited by examiner]
Akashi et al. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. vol. 404, p. 193-197 (Year: 2000). [cited by examiner]
Pimanda. Mesoderm-Derived PDGFRA+ Cells Regulate Emergence of Hematopoietic Stem Cells in the Dorsal Aorta. Experimental Hematology 64 (2018) S41-S51 (Year: 2018). [cited by examiner]
Betsholtz et al. Developmental roles of platelet-derived growth factors. BioEssays 23:494-507, 2001. (Year: 2001). [cited by examiner]
Dominici et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) vol. 8, No. 4, 315-317 (Year: 2006). [cited by examiner]
Extended European Search Report issued Sep. 30, 2021 in corresponding European Patent Application No. 18883298.4, 8 pages. [cited by applicant]
Alden et al., “In Vivo Endochondral Bone Formation Using a Bone Morphogenetic Protein 2 Adenoviral Vector”, Human Gene Therapy, 1999, vol. 10, pp. 2245-2253, 9 pages. [cited by applicant]
Andersson et al., “HMGB1 as a DNA-binding cytokine”, Journal of Leukocyte Biology, 2002, vol. 72, pp. 1084-1091, 8 pages. [cited by applicant]
Armiñán, et al., “Mesenchymal Stem Cells Provide Better Results Than Hematopoietic Precursors for the Treatment of Myocardial Infarction”, Journal of American College of Cardiology, 2010, vol. 55, No. 20, pp. 2244-2253,… [cited by applicant]
Arnau et al., “Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins”, Protein Expression and Purification, 2006, vol. 48, pp. 1-13, 13 pages. [cited by applicant]
Asch et al., “Lack of sensitivity of the electrocardiogram for detection of old myocardial infarction: A cardiac magnetic resonance imaging study”, American Heart Journal, 2006, vol. 152, No. 4, pp. 742-748, 7 pages. [cited by applicant]
Ball et al., “Mesenchymal stem cells and neovascularization: role of platelet-derived growth factor receptors”, J. Cell. Mol. Med., vol. 11, No. 5, 2007, pp. 1012-1030, 19 pages. [cited by applicant]
Basso et al., “Basso Mouse Scale for Locomotion Detects Differences in Recovery after Spinal Cord Injury in Five Common Mouse Strains”, Journal of Neurotrauma, 2006, vol. 23, No. 5, pp. 635-659, 19 pages. [cited by applicant]
Berry et al., “Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance”, Am J. Physiol Heart Circ Physiol, 2006, vol. 290, pp. H2196-H2203, 8 pages. [cited by applicant]
M. E. Bianchi, “High mobility group 1 protein (HMGB1) N-terminal peptide”, ADO80180 standard; peptide; 62 AA, 2004, 1 page. [cited by applicant]
Bittira et al., “Mobilization and homing of bone marrow stromal cells in myocardial infarction”, European Journal of Cardio-thoracic Surgery, 2003, vol. 24, pp. 393-398, 6 pages. [cited by applicant]
Blain et al., “δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches”, Blain and Straub Skeletal Muscle, 2011, vol. 1, pp. 1-12, 12 pages. [cited by applicant]
Brunner et al., “Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis”, T… [cited by applicant]
Zheng et al., BTF3 Nucleotide Sequence from “Sequencing and expression of complementary DNA for the general transcription factor BTF3”, Nature, 1990, vol. 344, pp. 556-559, 6 pages. [cited by applicant]
Cairo et al., “Results of a Phase I/II Trial of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Very Low Birthweight Neonates: Significant Induction of Circulatory Neutrophils, Monocytes, Platelets… [cited by applicant]
“Cardiomegaly”, Medical Definition and More from Merriam-Webster, https://www.merriam˜webster.com/medical/cardiomegaly, 2020, 2 pages. [cited by applicant]
“Cardiomyopathy: Symptoms, diagnosis and treatment”, Harvard Health Publishing, Harvard Medical School, 2014, 3 pages. [cited by applicant]
Castro et al., “Failure of Bone Marrow Cells to Transdifferentiate into Neural Cells in Vivo”, Science, 2002, vol. 297, p. 1299, 1 page. [cited by applicant]
Chen et al., “Human Bone Marrow Stromal Cell Cultures Conditioned by Traumatic Brain Tissue Extracts: Growth Factor Production”, Journal of Neuroscience Research, 2002, vol. 69, pp. 687-691, 5 pages. [cited by applicant]
Chen et al., “Coaxing bone marrow stromal mesenchymal stem cells towards neuronal differentiation: progress and uncertainties”, Cellular and Molecular Life Sciences, 2006, vol. 63, pp. 1649-1657, 9 pages. [cited by applicant]
J. Cole, III, “Pharmacologic Mobilization of Mesenchymal Stem Cells for Enhanced Bone Formation”, Master of Sciences Thesis submitted to Rush University, 2009, pp. 1-68, 82 pages. [cited by applicant]
DelaRosa et al., “Modulation of Adult Mesenchymal Stem Cells Activity by Toll-Like Receptors: Implications on Therapeutic Potential”, Mediators of Inflammation, 2010, vol. 2010, Article ID 865601, pp. 1-9, 9 pages. [cited by applicant]
Desai et al., “Tissue response to intraperitoneal implants of polyethylene oxide-modified polyethylene terephthalate”, Biomaterials, 1992, vol. 13, No. 8, pp. 505-510, Abstract, 1 page. [cited by applicant]
De Santis et al., “TNFα deficiency results in increased IL-1β in an early onset of spontaneous murine colitis”, Cell Death and Disease, 2017, vol. 8, e2993, pp. 1-7, 7 pages. [cited by applicant]
Eckert et al., “S100 Proteins in the Epidermis”, The Journal of Investigative Dermatology, 2004, vol. 123, pp. 23-33, 11 pages. [cited by applicant]
Erlandsson et al., “The nuclear protein HMGB 1 as a proinflammatory mediator”, Eur. J. Immunol., 2004, vol. 34, pp. 1503-1512, 10 pages. [cited by applicant]
Frankel et al., “Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor”, Protein Engineering, 2000, vol. 13, No. 8, pp. 575-581, 7 pages. [cited by applicant]
Fritsch et al., “A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy”, The Journal of Clinical Investigation, 2008, vol. 118, No. 5, pp. 1669-16… [cited by applicant]
Fukushima et al., “Registry Report on Heart Transplantation in Japan”, Circulation Journal, 2017, vol. 81, pp. 298-303, 6 pages. [cited by applicant]
Gallina et al., “A New Paradigm in Cardiac Regeneration: The Mesenchymal Stem Cell Secretome”, Stem Cells International, 2015, vol. 2015, Article ID 765846, pp. 1-10, 10 pages. [cited by applicant]
Goto et al., “Investigation of the application of myocardial regeneration inducing therapy using HMGB1 to cardiac infarction”, ISSN 1347-7919, 2017, vol. 16, p. 289, with English translation, 4 pages. [cited by applicant]
Gudjonsson et al., “Chapter 18 Psoriasis”, pp. 197-217, 21 pages. [cited by applicant]
S.A. Gueukdjian, “Intra-Arterial Injections in the Treatment of Peripheral Vascular Disease”, Postgrad Med J, 1955, vol. 31, pp. 30-31, 3 pages. [cited by applicant]
Guillot et al., “Response of Human Pulmonary Epithelial Cells to Lipopolysaccharide Involves Toll-like Receptor 4 (TLR4)-dependent Signaling Pathways”, The Journal of Biological Chemistry, 2004, vol. 279, No. 4, pp. 271… [cited by applicant]
Guo et al., “Monocyte Chemotactic Protein-1 Promotes the Myocardial Homing of Mesenchymal Stem Cells in Dilated Cardiomyopathy”, International Journal of Molecular Sciences, 2013, vol. 14, pp. 8164-8178, 15 pages. [cited by applicant]
Harrison et al., “Oxidation Regulates the Inflammatory Properties of the Murine S100 Protein S100A8”, J. Biol. Chem., 1998, vol. 274, No. 13, pp. 8561-8569, 10 pages. [cited by applicant]
Healthwise Staff, “Age-related Macular Degeneration”, University of Michigan Health System, 2015, http://www.uofmhealth.org/health-library/hw176039, 3 pages. [cited by applicant]
He et al., “HMGB1 Ameliorates Inflammatory Bowel Disease by Inducing Circulating Mesenchymal Stem Cells”, The 17 [cited by applicant]
Heil et al., “An engineered heparin-binding form of VEGF-E (hbVEGF-E)”, Angiogenesis, 2003, vol. 6, No. 3, pp. 201-211, 11 pages. [cited by applicant]
Herrera et al., “Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury”, Kidney International, 2007, vol. 72, pp. 430-441, 12 pages. [cited by applicant]
Hiratsuka et al., “Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis”, Nature Cell Biology, 2006, vol. 8, No. 12, pp. 1369-1375, 15 pages. [cited by applicant]
HMGBiotech, “BoxA from HMGB1, human & mouse, LPS-free”, Product Nos. HM-012, HM-013, HM-014, HMGBiotech Srl, 2008, http://www.hmgbiotech.com/products.php?ID=91, accessed 2017 from internet, 2 pages. [cited by applicant]
HMGBiotech, “BoxA from HMGB1, human & mouse, LPS-free-Datasheet”, Product Nos. HM-012, HM-013, HM-014, HMGBiotech Srl, 2008, http://www.hmgbiotech.com/upload/documenti/0515122144_boxa, 1 page. [cited by applicant]
Matunis et al., HNRPK_HUMAN Seqeunce from “Cahracterization and primary structure of the poly©-binding heterogeneous nuclear ribonucleoprotein complex K protein”, Mol. Cell. Biol., 1992, vol. 12, pp. 164-171; UNiProt, N… [cited by applicant]
Hori et al., “The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin”, Journal of Biological Chemistry, 1995, vol. 270, No. 43, pp. 25752-25761, 10 pages. [cited by applicant]
Hornef et al., “Toll-like Receptor 4 Resides in the Golgi Apparatus and Colocalizes with Internalized Lipopolysaccharide in Intestinal Epithelial Cells”, J. Exp. Med., 2002, vol. 195, No. 5, pp. 559-570, 12 pages. [cited by applicant]
V.J. Hruby, “Designing Peptide Receptor Agonists and Antagonists”, Nature Reviews Drug Discovery, 2002, vol. 1, pp. 847-858, 15 pages. [cited by applicant]
Hu et al., “Role of high-mobility group box 1 protein in inflammatory bowel disease”, Inflamm. Res., 2015, vol. 64, pp. 557-563, 7 pages. [cited by applicant]
Ichinose et al., “Antiangiogenic Endostatin Peptide Ameliorates Renal Alternations in the Early Stage of a Type 1 Diabetic Nephropathy Model”, Diabetes, 2005, vol. 54, No. 10, pp. 2891-2903, 13 pages. [cited by applicant]
Instruction Manual of HiTrap Chelating HP, Amersham Biosciences, 2003, pp. 1-6, 6 pages. [cited by applicant]
Ishikane et al., “Therapeutic application of allogenic fetal membrane-derived mesenchymal stem cells transplantation in regenerative medicine”, Pharmaceutical Bulletin of Fukuoka University, 2011, vol. 11, with English … [cited by applicant]
Ishikane et al., Development of multi-growth factor secreted fetal membrane-derived mesenchymal stem cell sheets, Grants-in-Aid for Scientific Research, 2014, with English Translation, pp. 1-6, 14 pages. [cited by applicant]
Jansen et al., “Transplantation of hematopoietic stem cells from the peripheral blood”, Journal of Cellular and Molecular Medicine, 2005, vol. 9, No. 1, pp. 37-50, 14 pages. [cited by applicant]
Jiang et al., “Pluripotency of mesenchymal stem cells derived from adult marrow”, Nature, 2002, vol. 418, pp. 41-49, 9 pages. [cited by applicant]
Jiao et al., “Researchers find nerve damage may precede diabetic retinopathy”, EurekAlert! Science News, 2016, https://www.eurekalert.org/pub-releases/2016-04/uoih-rfv042616.php, 2 pages. [cited by applicant]
Jin et al., “Isolating culture and induced differentiation of marrow mesenchyma stem cells”, Principles and Protocols of Tissue Engineering, 2004, pp. 277-278, with English Translation, 6 pages. [cited by applicant]
Kaneda et al., “Tissue repair mechanism by bone-marrow-derived stem cells”, Experimental Mediciner, 2013, vol. 31, No. 5, pp. 655-661, with English Translation, 17 pages. [cited by applicant]
Kassis et al., “Isolation of mesenchymal stem cells from G-CSF mobilized human peripheral blood using fibrin microbeads”, Bone Marrow Transplantation, 2006, vol. 37, No. 10, pp. 967-976, 10 pages. [cited by applicant]
Kido et al., “Abstract 15756: The Administration of High-morbidity Group Box 1 Fragment Prevents Deterioration of Cardiac Performance by Enhancement of Bone-marrow Mesenchymal Stem Cells Homing in the Delta-sarcoglycan-… [cited by applicant]
Kikuchi et al., “Systemic administration of HMGB1 improves bleomycin-induced skin fibrosis by locally accumulating bone marrow mesenchymal stem cells”, Regenerative Medicine, 2017, vol. 16, p. 422, with English Translat… [cited by applicant]
Kim et al., “Skin Regeneration Using Keratinocytes and Dermal Fibroblasts Cultured on Biodegradable Microspherical Polymer Scaffolds”, Journal of Biomedical Materials Research Part B: Applied Biomaterials, 2005, vol. 75… [cited by applicant]
Kirov, et al., “In Vivo 2-Photon Microscopy Reveals G-CSF Enhanced Mobilization and Targeting of Neo-Endogenous Bone Marrow Stromal Cells to Stroke Injury Sites”, Stroke, 2009, vol. 40, No. 4, pp. 1-2, e133, Abstract No… [cited by applicant]
Kohno et al., “High Mobility Group Box 1 Protein is Associated with Post-Infarction Healing Process and Left Ventricular Remodeling”, Circulation Journal., 2008, vol. 72, Suppl. 1, P J-004, pp. 510-511, 2 pages. [cited by applicant]
Komurasaki, et al., “555 Systemic HMGB1 Administration Ameliorated Bleomycin-Induced Skin Fibrosis by Promoting Accumulation of Bone Marrow-Derived Mesenchymal Stem Cells to the Lesion”, Journal of Investigative Dermato… [cited by applicant]
Komurasaki, et al., “HMGB1 Ameliorates Bleomycin-Induced Skin Fibrosis by Promoting Accumulation of Mesenchymal Stem Cells to the Lesion”, The 48 [cited by applicant]
Koren-Morag et al., “White Blood Cell Count and the Incidence of Ischemic Stroke in Coronary Heart Disease Patients”, The American Journal of Medicine, 2005, vol. 118, pp. 1004-1009, 6 pages. [cited by applicant]
Lanza et al., “Essentials of Stem Cell Biology—Chapter 27, Mesenchymal Stem Cells”, Elsevier Academic Press, 2006, pp. 205-210, 8 pages. [cited by applicant]
LaRosa et al., “Glycine max protein SEQ ID No. 211221”, Geneseq Accession No. AFQ20044, 2007, 1 page. [cited by applicant]
Lemp et al., “The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007)”, The Ocular Surface, 2007, vol. 5, No. 2, pp. 75… [cited by applicant]
Li, et al., “Nonviral gene therapy: promises and challenges”, Gene Therapy, 2000, vol. 7, pp. 31-34, 4 pages. [cited by applicant]
Li et al., “Heat-Shock Proteins”, Current Protocols in Immunology, 2003, Supplement 58, A.IT.1-A.IT.6, 6 pages. [cited by applicant]
Li et al., “Advancement of Human Multiply, Sex health and Reproductive Medical Science”, Peking University Medical Press, 2007, 1 [cited by applicant]
Limana et al., “HMGB1 Attenuates Cardiac Remodelling in the Failing Heart via Enhanced Cardiac Regeneration and miR-206-Mediated Inhibition of TIMP-3”, PLoS ONE, 2011, vol. 6, No. 6, e19845, pp. 1-11, 11 pages. [cited by applicant]
Liotta et al., “Toll-Like Receptors 3 ad 4 are Expressed by Human Bone Marrow-Derived Mesenchymal Stem Cells and Can Inhibit Their T-Cell Modulatory Activity by Impairing Notch Signaling”, Stem Cells, 2008, vol. 26, pp.… [cited by applicant]
Liu et al., “Human Placental Extract Stimulates Liver Regeneration in Rats”, Biol. Pharm. Bull., 1998, vol. 21, No. 1, pp. 44-49, 6 pages. [cited by applicant]
Lonza BenchGuides, “Poietics hMSC Human Mesenchymal Stem Cells and Media”, Document #TS-PT-212-7, 2008, 2 pages. [cited by applicant]
Lund et al., “The Registry of the International Society for Heart and Lung Transplantation: Thirty-Third Adult Heart Transplantation Report—2016; Focus Theme: Primary Diagnostic Indications for Transplant”, The Journal … [cited by applicant]
Mansbridge et al., “Skin Tissue Engineering”, J. Biomater, Sci. Polymer, Edn, 2008, vol. 19, No. 8, pp. 955-968, 15 pages. [cited by applicant]
Maron et al., “Contemporary Definitions and Classification of the Cardiomyopathies”, Circulation, 2006, vol. 113, pp. 1807-1816, 10 pages. [cited by applicant]
Maruyama et al., “Inflammation and HMGB1/RAGE system”, Kekkan Igaku, 2005, vol. 6, No. 5, pp. 519-525, with English Translation, 15 pages. [cited by applicant]
Matsumoto et al., “Up-Regulation of Hepatocyte Growth Factor Gene Expression by Inerleukin-1 in Human Skin Fibrosis”, Biochemical and Biophysical Research Communications, 1992, vol. 188, No. 1, pp. 235-243, 9 pages. [cited by applicant]
Meng et al., “HMGB1 induces migration of human bone marrow-derived mesenchymal stem cells”, Bulletin of the Academy of Military Medical Sciences, 2006, vol. 30, No. 3, pp. 213-216, with English Translation, 11 pages. [cited by applicant]
Meng et al., “High Mobility Group Box 1 Protein Inhibits the Proliferation of Human Mesenchymal Stem Cells and Promotes Their Migration and Differentiation along Osteoblastic Pathway”, Stem Cells and Development, 2008, … [cited by applicant]
Mori et al., “Stem Cells/ES Cells—Mesenchymal Stem Cells—Human Bone Marrow Derived Mesenchymal Stem Cells”, Saisei Iryou—Regenerative Medicine, 2005, vol. 4, No. 3, pp. 421-429, 24 pages. [cited by applicant]
Morosetti et al., “MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle”, PNAS, 2006, vol. 103, No. 45, pp. 16995-17000, 6 pages. [cited by applicant]
“Blood Collection: The Mouse”, Mouse care guidance from the Institutional Animal Care and Use Committee (IACUC) at University of California, San Francisco; iacuc.ucsf.edu/Policies/BloodCollectionMice.doc; accessed 2014,… [cited by applicant]
Muhamed et al., “Phenotypic Modulation of Cell Types around Implanted Polyethylene Terephthalate Fabric in Rabbit Muscle”, Toxicologic Pathology, 2013, vol. 41, pp. 497-507, 11 pages. [cited by applicant]
Musumeci et al., “An overview of HMGB 1 inhibitors as potential therapeutic agents in HMGB1-related pathologies”, Pharmacology & Therapeutics, 2014, vol. 141, pp. 347-357, 11 pages. [cited by applicant]
Nakajima et al., “Dynamics and Role of High Mobility Group Box-1 (HMGB-1) in Injured Spinal Cord”, Nihon Seikei Geka Gakkai Zasshi, J. Jpn. Orthop. Assoc., 2010, vol. 84, No. 8, p. S0150, with English Translation, 2 pag… [cited by applicant]
Nakanishi et al., “Membrane Potential-Regulated Ca [cited by applicant]
Narumi et al., “High-mobility Group Box 1 Attenuates Mitochondrial Dysfunction and Apoptosis via Heat Shock Protein Beta 1 Induction in Doxorubicin-induced Cardiomyopathy”, Bulletin of Yamagata University (Medical Scien… [cited by applicant]
NCBI, “Old myocardial infarction”, MedGen UID: 57612, retrieved from internet Jan. 19, 2022, 4 pages, https://www.ncbi.nlm.nih.gov/medgen/57612. [cited by applicant]
Nickoloff et al., “Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities”, Journal of Clinical Investigation, 2004, vol. 113, No. 12, pp. 1664-1675, 12 pages. [cited by applicant]
O'Callaghan et al., “HMGB1 as a key mediator of tissue response to injury: roles in inflammation and tissue repair”, European Surgery, 2006, vol. 38, pp. 283-292, 18 pages. [cited by applicant]
Opitz et al., “Toll-Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal Stem Cells by Inducing Indoleamine-2,3-dioxygenase-1 via Interferon-β and Protein Kinase R”… [cited by applicant]
Otsuru et al., BMP-2 mobilizes robust bone marrow mesenchymal progenitor cells to the circulating blood in bone regeneration, The 28 [cited by applicant]
Ozaki et al. “Comprehensive Analysis of Chemotactic Factors for Bone Marrow Mesenchymal Stem Cells”, Stem Cells and Development, 2007, vol. 16, pp. 119-129, 11 pages. [cited by applicant]
PA2G4_HUMAN Sequence, Accession No. Q9UQ80, Apr. 2001, 9 pages. [cited by applicant]
Panepucci et al., “Abstract #4427: Comparison of Gene Expression of Mesenchymal Stem Cells from the Umbilical Cord and from the Bone Marrow”, Blood, 2003, vol. 16, No. 102, Abstract, 1 page. [cited by applicant]
Panepucci et al., “Comparison of Gene Expression of Umbilical Cord Vein and Bone Marrow-Derived Mesenchymal Stem Cells”, Stem Cells, 2004, vol. 22 No. 7, pp. 1263-1278, 16 pages. [cited by applicant]
Paul et al., “Stromal Cell-Associated Hematopoiesis: Immortalization and Characterization of a Primate Bone Marrow-Derived Stromal Cell Line”, Blood, 1991, vol. 77, No. 8, pp. 1723-1733, 11 pages. [cited by applicant]
Pevsner-Fischer et al., “Toll-like receptors and their ligands control mesenchymal stem cell functions”, Blood, 2007, vol. 109, No. 4, pp. 1422-1432, 11 pages. [cited by applicant]
PFD5_HUMAN Sequence, Accession No. Q99471, Nov. 1997, 6 pages. [cited by applicant]
NPM_HUMAN Sequence, Accession No. P06748, Jan. 1988, 15 pages. [cited by applicant]
PRS6A_HUMAN Sequence, Accession No. P17980, Nov. 1990, 9 pages. [cited by applicant]
Pusterla et al., “High mobility group B2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group B1”, Autoimmunity, 2009, vol. 42, No. 4, pp. 308-310, 27 pages. [cited by applicant]
Quertainmont et al., “Mesenchymal Stem Cell Graft Improves Recovery after Spinal Cord Injury in Adult Rats through Neurotrophic and Pro-Angiogenic Actions”, PLoS ONE, 2012, vol. 7, No. 6, pp. 1-15, 15 pages. [cited by applicant]
Racanelli et al., “The Liver as an Immunological Organ”, Hepatology, 2006, vol. 43, No. 2, pp. S54-S62, 9 pages. [cited by applicant]
Rahimi-Movaghar et al., “Effect of Decompression on Complete Spinal Cord Injury in Rats”, International Journal of Neuroscience, 2008, vol. 118, pp. 1359-1373, 15 pages. [cited by applicant]
Raicevic et al., “Inflammation modified the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells”, Human Immunology, 2010, vol. 71, pp. 235-244, 10 pages. [cited by applicant]
Robinson et al., “The S100 Family Heterodimer, MRP-8/14, Binds with High Affinity to Heparin and Heparan Sulfate Glycosaminoglycans on Endothelial Cells”, The Journal of Biological Chemistry, 2002, vol. 277, No. 5, pp. … [cited by applicant]
Ross et al., “Histology: A Text and Atlas: With Correlated Cell and Molecular Biology”, https://books.google.com/books?id=5vx9DwAAQBAJ&lr=source=gbs_navlinks_s[Jan. 19, 2022], 2 pages. [cited by applicant]
Ryckman et al., “Proinflammatory Activities of S100: Proteins S100A8, S100A9, and S100A8/A9 Induced Neutrophil Chemotaxis and Adhesion”, The Journal of Immunology, 2003, vol. 170, pp. 3233-3242, 10 pages. [cited by applicant]
Santamaria-Kisiel et al., “Calcium-dependent and -independent interactions of the S100 protein family”, Biochem. J., 2006, vol. 396, pp. 201-214, 14 pages. [cited by applicant]
J. Saver, “Time is Brain—Quantified”, Stroke, 2006, vol. 37, pp. 263-266, 4 pages. [cited by applicant]
Schäffer et al., “Wound Fluid Inhibits Wound Fibroblast Nitric Oxide Synthesis”, Journal of Surgical Research, 2004, vol. 122, pp. 43-48, 6 pages. [cited by applicant]
Schön et al., “Psoriasis”, New England Journal of Medicine, 2005, vol. 352, No. 18, pp. 1899-1912, 14 pages. [cited by applicant]
Scoote et al., “Pathophysiology of Heart Failure”, Chapter 19, Essential Cardiology: Principles and Practice, 2 [cited by applicant]
Seffernick et al., “Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different”, Journal of Bacteriology, 2001, vol. 183, No. 8, pp. 2405-2410, 6 pages. [cited by applicant]
Selected cardiac diagnoses and ICD-10 codes, 1 page. [cited by applicant]
Seong et al., “Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses”, Nature Reviews, Immunology, 2004, vol. 4, pp. 469-478, 10 pages. [cited by applicant]
Shibata et al., Fibroblast growth-stimulating activity of S100A9 (MRP-14), Eur. J. Biochem., 2004, vol. 271, pp. 2137-2143, 7 pages. [cited by applicant]
Shing et al., “Heparin Affinity: Purification of a Tumor-Derived Capillary Endothelial Cell Growth Factor”, Science, 1984, vol. 223, pp. 1296-1299, 4 pages. [cited by applicant]
Simard et al., “Bone Marrow-Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation in Alzheimer's Disease”, Neuron, 2006, vol. 49, pp. 489-502, 14 pages. [cited by applicant]
Slater et al., “Endometriotic cells exhibit metaplastic change and oxidative DNA damage as well as decreased function, compared to normal endometrium”, Journal of Molecular Histology, 2005, vol. 36, pp. 257-263, 7 pages. [cited by applicant]
Somia et al., “Gene Therapy: Trials and Tribulations”, Nature Reviews, Genetics, 2000, vol. 1, pp. 91-99, 9 pages. [cited by applicant]
Soo et al., “Heat Shock Proteins as Novel Therapeutic Targets in Cancer”, in vivo, 2008, vol. 22, pp. 311-316, 5 pages. [cited by applicant]
SP16H_HUMAN Sequence, Accession No. Q9Y5B9, Jul. 2006, 10 pages. [cited by applicant]
Takahashi et al., “Effects of HMGB1 on Postinfarction Chronic Heart-Failure—Novel Mechanism Regarding Therapeutic Effects of Cell Therapy”, 2001, William Harvey Research Institute, with English Translation, I-E-19, 3 pa… [cited by applicant]
Takami et al., “Synergistic induction of hepatocyte growth factor in human skin fibroblasts by the inflammatory cytokines interleukin-1 and interferon-γ” Biochemical and Biophysical Research Communications, 2005, vol. 3… [cited by applicant]
Takeishi et al., “Importance of inflammation and immune response in heart failure—Toll-like receptor-mediated signaling pathway and ventricular remodeling after myocardial infarction”, Journal of Clinical and Experiment… [cited by applicant]
Tamai et al., “New Wave of Wound Healing”, Japanese Journal of Dermatology, 2008, vol. 118, No. 4, EL28-3-4, with English Translation, 2 pages. [cited by applicant]
Tamai et al., “Supporting Information”, www.pnas.org/egi/content/short/1016753108, pp. 1-12, 12 pages. [cited by applicant]
U.S. Appl. No. 11/997,475, “Mesenchymal Stem Cell Inducer, Tissue Regeneration Promotor and Method of Preparing Mesenchymal Stem Cell”, Abandoned—Incomplete Application (Pre-examination), 37 pages. [cited by applicant]
U.S. Appl. No. 17/517,967, filed Nov. 3, 2021, “Agents for Promoting Tissue Regeneration by Recruiting Bone Marrow Mesenchymal Stem Cells and/or Pluripotent Stem Cells into Blood”, 113 pages. [cited by applicant]
Tamilselvi et al., “Association of Disease Severity with IL-1 levels in Methotrexate-treated Psoriasis Patients”, Scandinavian Journal of Immunology, 2013, vol. 78, pp. 545-553, 9 pages. [cited by applicant]
Tang et al., “Fibrin(ogen) Mediates Acute Inflammatory Responses to Biomaterials”, J. Exp. Med, 1993, vol. 178, pp. 2147-2156, 10 pages. [cited by applicant]
Tatsumi et al., “HGF/SF Is Present in Normal Adult Skeletal Muscle and Is Capable of Activating Satellite Cells”, Developmental Biology, 1998, vol. 194, pp. 114-128, 15 pages. [cited by applicant]
Teoh et al., “Low-Dose TNF-α Protects Against Hepatic Ischemia-Reperfusion Injury in Mice: Implications for Preconditioning”, Hepatology, 2003, vol. 37, No. 1, pp. 118-128, 11 pages. [cited by applicant]
Thorey et al., “The Ca [cited by applicant]
Tokuriki et al., “Stability effects of mutations and protein evolvability”, Current Opinion in Structural Biology, 2009, vol. 19, pp. 596-604, 9 pages. [cited by applicant]
Türker et al., “Nasal route and drug delivery systems”, Pharmacy World and Science, 2004, vol. 26, pp. 137-142, 6 pages. [cited by applicant]
Uchida et al., “The chemotactic activity of PDGF-bb BMP-2, and FGF-2 towards committed and uncommitted mesenchymal stem cells”, The Journal of Japanese Orthopedic Surgical Society, 2005, vol. 79, No. 8, S832, 1-P6-6., w… [cited by applicant]
Ueta et al., “Intracellularly Expressed TLR2s and TLR4s Contribution to an Immunosilent Environment at the Ocular Mucosal Epithelium”, The Journal of Immunology, 2004, vol. 173, No. 5, pp. 3337-3347, 12 pages. [cited by applicant]
Uronen-Hansson et al., “Toll-like Receptor 2 (TLR2) and TLR4 are Present Inside Human Dendritic Cells, Associates with Microtubules and the Golgi Apparatus but are not Detectable on the Cell Surface: Integrity of Microt… [cited by applicant]
User Manual for StemCell Technologies, “Enumeration, Expansion, and Differentiation of Human Mesenchymal Progenitor Cells Using MesenCult”, StemCell Technologies, 2007, Version 2.2.0., 24 pages. [cited by applicant]
Vandal et al., “Blockade of S100A8 and S100A9 Suppresses Neutrophil Migration in Response to Lipopolysaccharide”, The Journal of Immunology, 2003, vol. 171, No. 5, pp. 2602-2609, 8 pages. [cited by applicant]
Walfish et al., “Pathophysiology of Crohn Disease”, Merck Manual Professional Version, Merck Sharp & Dohme Corp., 2020, 7 pages. [cited by applicant]
Walfish et al., “Overview of Inflammatory Bowel Disease”, Merck Manual Professional Version, Merck Sharp & Dohme Corp., 2020, 3 pages. [cited by applicant]
Walfish et al., “Ulcerative Colitis”, Merck Manual Professional Version, Merck Sharp & Dohme Corp., 2020, 8 pages. [cited by applicant]
Wang et al., “High mobility group protein B1 and research progress of its biological effect”, Journal of Chinese Modern Surgery, 2006, vol. 3, No. 22, pp. 1806-1809, with English translation, 15 pages. [cited by applicant]
Wang et al., “Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture”, Experimental Hematology, 2002, vol. 30, pp. 831-836, 6 pages. [cited by applicant]
Wang et al., “Theories and Technologies for Stem Cells”, Series of the 21st Century Biotechnologies, Science Press, 2005, vol. 5, pp. 58-61, with English translation, titled 16 pages. [cited by applicant]
Wang et al., “Rate of Evolution in Brain-Expressed Genes in Humans and Other Primates”, PLoS Biol., 2007, vol. 5, No. 2: e13, pp. 0335-0342, 8 pages. [cited by applicant]
Wang et al., “Intravenous administration of bone marrow mesenchymal stromal cells is safe for the lung in a chronic myocardial infarction model”, Regen. Med., 2011, vol. 6, No. 2, pp. 179-190, 12 pages. [cited by applicant]
Y. Wang, “Biology of hematopoietic stem cell and the research method thereof”, Science Press, 2007, 1 [cited by applicant]
Weintraub et al., “Dilated cardiomyopathy”, Lancet, 2017, vol. 390, pp. 400-414, 15 pages. [cited by applicant]
Wexler et al., “Adult Bone Marrow is a Rich Source of Human Mesenchymal ‘Stem’ Cells but Umbilical Cord and Mobilized Adult Blood are Not”, British Journal of Haematology, 2003, vol. 121, No. 2, pp. 368-374, 7 pages. [cited by applicant]
Whisstock et al., “Prediction of Protein Function from Protein Sequence and Structure”, Quarterly Reviews of Biophysics, 2003, vol. 36, No. 3, pp. 307-340, 34 pages. [cited by applicant]
Witkowski et al., “Conversion of a β-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine”, Biochemistry, 1999, vol. 38, pp. 11643-11650, 8 pages. [cited by applicant]
Wolf et al., “From the Periphery of the Glomerular Capillary Wall Toward the Center of Disease”, Diabetes, 2005, vol. 54, pp. 1626-1634, 9 pages. [cited by applicant]
Woodbury et al., “Adult Rat and Human Bone Marrow Stromal Cells Differentiate into Neurons”, Journal of Neuroscience Research, 2000, vol. 61, pp. 364-370, 7 pages. [cited by applicant]
Wu et al., “Mesenchymal Stem Cells Enhance Wound Healing Through Differentiation and Angiogenesis”, Stem Cells, 2007, vol. 25, pp. 2648-2659, 12 pages. [cited by applicant]
Yamaoka et al., “1043 Systemic delivery of HMGB1 peptide ameliorates imiquimod-induced psoriasis-like dermatitis”, Journal of Investigative Dermatology, 2018, vol. 138, No. 5, S177, 2 pages. [cited by applicant]
YBOX1_HUMAN Sequence, Accession No. P67809, Oct. 2004, 11 pages. [cited by applicant]
Yuan et al., “Differentiation of Mesenchymal Stem Cells in Cardiomyogenic Cells Under the Induction of Myocardial Cell Lysate”, Chinese Journal of Cardiology, 2005, vol. 33, No. 2, pp. 170-173, with English Translation,… [cited by applicant]
Yu et al., “Impact of Repeated Intravenous Bone Marrow Mesenchymal Stem Cells Infusion on Myocardial Collagen Network Remodeling in a Rat Model of Doxorubicin-Induced Dilated Cardiomyopathy”, Molecular and Cellular Bioc… [cited by applicant]
Zhou et al., “Section 2 The translation process of genetic information”, Molecular Genetics, 1992, pp. 141-143, 7 pages. [cited by applicant]
Zhou et al., “High mobility group box 1 protein attenuates myocardial ischemia reperfusion injury via inhibition of the p38 mitogen-activated protein kinase signaling pathway”, Experimental and Therapeutic Medicine, 201… [cited by applicant]
International Preliminary Report on Patentability issued Apr. 27, 2021 in International (PCT) Application No. PCT/JP2019/042015. [cited by applicant]
International Search Report issued Jan. 1, 2020 in International (PCT) Application No. PCT/JP2019/042015. [cited by applicant]
Taniguchi et al., “Stage-Specific Secretion of HMG1 in Cartilage Regulates Endochondral Ossification”, Molecular and Cellular Biology, 2007, vol. 27. No. 16, pp. 5650-5663, 14 pages. [cited by applicant]
Tamai et al., “Chapter 2 Various disease models and drug discovery research, 7. Skin and inflammatory disease, 2) Prospects for the development of in vivo regenerative induction drug using in vivo bone marrow mesenchyma… [cited by applicant]
Lee et al., “Fully reduced HMGB1 accelerates the regeneration of multiple tissues by transitioning stem cells to G [cited by applicant]
Sugawara et al., “Artificial organ—Recent advanced, Recent advanced in cartilage loss treatment by cultured cartilage”, Jinko Zoki, 2013, vol. 42, No. 3, pp. 198-200, (with partial English Translation) 4 pages. [cited by applicant]
Freitag et al., “The effect of autologous adipose derived mesenchymal stem cell therapy in the treatment of a large osteochondral defect of the knee following unsuccessful surgical intervention of osteochondritis dissec… [cited by applicant]
Bianchi et al., “The DNA binding site of HMG1 protein is composed of two similar segments (HMG boxes), both of which have counterparts in other eukaryotic regulatory proteins”, EMBO Journal, 1992, vol. 11, No. 3, pp. 10… [cited by applicant]
Michael Bustin, Regulation of DNA-Dependent Activities by the Functional Motifs of the High-Mobility Group Chromosomal Proteins, Molecular and Cellular Biology, 1999, vol. 19, No. 8, pp. 5237-5246, 10 pages. [cited by applicant]
Chamberlain et al., “Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing”, Stem Cells, 2007, vol. 11, No. 11, pp. 2739-2749, 11 pages. [cited by applicant]
Charoonpatrapong et al., “HMGB1 Expression and Release by Bone Cells”, Journal of Cellular Physiology, 2006, vol. 270, pp. 480-490, 11 pages. [cited by applicant]
Chen et al., “Involvement of high mobility group box-1 in imiquimod-induced psoriasis-like mice model”, Journal of Dermatology, 2017, vol. 44, pp. 573-581, 9 pages. [cited by applicant]
Chopp et al., “Treatment of neural injury with marrow stromal cells”, The Lancet Neurology, 2002, vol. 1, pp. 92-100, 9 pages. [cited by applicant]
Chou et al., “Identity of nuclear high-mobility-group protein, HMG-1, and sulfoglucuronyl carbohydrate-binding protein, SBP-1, in brain”, Journal of Neurochemistry, 2001, vol. 77, pp. 120-131, 12 pages. [cited by applicant]
De Souza et al., “HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis”, Autoimmunity Reviews, 2012, vol. 11, pp. 909-917, 9 pages. [cited by applicant]
Degryse et al., “The High Mobility Group (HMG) Boxes of the Nuclear Protein HMG1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells”, Journal of Cell Biology, 2001, vol. 52, No. 6, pp. 1197-120… [cited by applicant]
Dong et al., “HMGB1 Protein Does Not Mediate the Inflammatory Response in Spontaneous Spinal Cord Regeneration”, Journal of Biological Chemistry, 2013, vol. 288, No. 25, pp. 18204-18218, 15 pages. [cited by applicant]
Ehrchen et al., “The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer”, Journal of Leukocyte Biology, 2009, vol. 86, No. 3, pp. 557-566, 11 … [cited by applicant]
Esposito et al., “Melatonin reduces stress-activated/mitogen-activated protein kinases in spinal cord injury”, Journal of Pineal Research, 2009, vol. 46. No. 1, pp. 79-86, 8 pages. [cited by applicant]
Fang et al., “HMGB1 Contributes to Regeneration After Spinal Cord Injury in Adult Zebrafish”, Mol Neurobiol, 2014, vol. 49, pp. 472-483, 12 pages. [cited by applicant]
Forte et al., “Hepatocyte Growth Factor Effects on Mesenchymal Stem Cells: Proliferation, Migration, and Differentiation”, Stem Cells, 2006, vol. 24, pp. 23-33, 11 pages. [cited by applicant]
Fujii et al., “Roles of Bone Morphogenetic Protein Type I Receptors and Smad Protein in Osteoblast and Chondroblast Differentiation”, Molecular Biology of the Cell, 1999, vol. 10, pp. 3801-3813, 13 pages. [cited by applicant]
Germani et al., “Pivotal Advance: High-mobility group box 1 protein—a cytokine with a role in cardiac repair”, Journal of Leukocyte Biology, 2007, vol. 81, pp. 41-45, 6 pages. [cited by applicant]
Gong et al., “The Anti-Inflammatory Activity of HMGB1 A Box Is Enhanced When Fused with C-Terminal Acidic Tail”, Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 915234, 6 pages. [cited by applicant]
Granero-Molto et al., “Role of mesenchymal stem cells in regenerative medicine: application to bone and cartilage repair”, Expert Opinion on Biological Therapy, 2008, vol. 8, No. 3, pp. 255-268, 14 pages. [cited by applicant]
Harris et al., “The nuclear protein HMGB1 as a proinflammatory mediator”, Eur. J. Immunol., 2004, vol. 34, pp. 1503-1512, 10 pages. [cited by applicant]
Harris et al., “Alarmin (g) news about danger, Workshop on Innate Danger Signals and HMGB1”, EMBO reports, 2006, vol. 7, pp. 774-778, 5 pages. [cited by applicant]
Huttunen et al., “Receptor for Advanced Glycation End Products-binding COOH-Terminal Motif of Amphoterin Inhibits Invasive Migration and Metastasis”, Cancer Research, 2002, vol. 62, pp. 4805-4811, 8 pages. [cited by applicant]
Jayaraman et al. “High mobility group protein-1 (HMG-1) is a unique activator of p53”, Genes & Development, 1998, vol. 12, pp. 462-472, 11 pages. [cited by applicant]
Kawabata et al., “High Mobility Group Box 1 Is Upregulated After Spinal Cord Injury and Is Associated With Neuronal Cell Apoptosis”, Spine, vol. 35 No. 11, pp. 1109-1115, 7 pages. [cited by applicant]
Kern et al., “Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue”, Stem Cells, 2006, vol. 26, pp. 1294-1301, 8 pages. [cited by applicant]
Kessler et al., “Tissue engineering and cartilage”, Organogenesis, 2008, vol. 4, No. 1, pp. 28-32, 5 pages. [cited by applicant]
Kikuchi et al., “HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review)”, Experimental and Therapeutic Medicine, 2011, vol. 2, pp. 767-770, 4 pages. [cited by applicant]
Kitahara et al., “High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice”, Cardiovascular Research, 2008, vol. 80, pp. 40-46, 7 pages. [cited by applicant]
Koc et al., “Mesenchymal stem cells: heading into the clinic”, Bone Marrow Transplantation, 2001, vol. 27, pp. 235-239, 5 pages. [cited by applicant]
Kokkola et al., “RAGE is the Major Receptor for the Proinflammatory Activity of HMGB1 in Rodent Marcophages”, Scandinavian Journal of Immunology, 2005, vol. 61, pp. 1-9; 9 pages. [cited by applicant]
Laflamme et al., “Regenerating the heart”, Nature Biotechnology, 2005, vol. 23, No. 7, pp. 845-856, 12 pages. [cited by applicant]
Li et al., “Emerging role of HMGB1 in fibrotic diseases”, J. Cell. Mol. Med., 2014, vol. 18, No. 12, pp. 2231-2339, 9 pages. [cited by applicant]
Limana et al., “Exogenous High-Mobility Group Box 1 Protein Induces Myocardial Regeneration After Infarction via Enhanced Cardiac C-Kit [cited by applicant]
Lin et al., “The Isolation of Novel Mesenchymal Stromal Cell Chemotactic Factors from the Conditioned Medium of Tumor Cells”, Exp Cell Res., 2008, vol. 314, No. 17, pp. 3107-3117, 20 pages. [cited by applicant]
Martin-Murphy et al., “The Role of Damage Associated Molecular Pattern Molecules in Acetaminophen-Induced Liver Injury in Mice”, Toxicol Lett., 2010, vol. 192, No. 3, pp. 387-394, 20 pages. [cited by applicant]
Merenmies et al., “30-kDa Heparin-binding Protein of Brain (Amphoterin) Involved in Neurite Outgrowth”, Journal of Biological Chemistry, 1991, vol. 226, No. 25, pp. 16722-16729, 8 pages. [cited by applicant]
Mistry et al., “Recombinant HMG1 Protein Produced in Pichia pastoris: A Nonviral Gene Delivery Agent” BioTechniques, 1997, vol. 22, pp. 718-729, 11 pages.q [cited by applicant]
Muhammad et al., “The HMGB1 Receptor RAGE Medicates Ischemic Brain Damage”, Journal of Neuroscience, 2008, vol. 28, No. 46, pp. 12023-12031, 9 pages. [cited by applicant]
Müller et al., The double life of HMGB1 chromatin protein: architectural factor and extracellular signal, EMBO Journal, 2001, vol. 20, No. 16, pp. 4337-4340, 4 pages. [cited by applicant]
Nakamura et al., “p38 Mitogen-Activated Protein Kinase Functionally Contributes to Chondrogenesis Induced by Growth/Differentiation Factor-5 in ATDC5 Cells”, Experimental Cell Research, 1999, vol. 250, pp. 351-363, 13 p… [cited by applicant]
Narumi et al., “High-Mobility group box 1-mediated heat shock protein beta 1 expression attenuates mitochondrial dysfunction and apoptosis”, Journal of Molecular and Cellular Cardiology, 2015, vol. 82, pp. 1-12, 12 page… [cited by applicant]
Palumbo et al., “Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-κB activation”, Journal of Cell Biology, 2007, vol. 179, No. 1, pp. 33-40, 8 pages. [cited by applicant]
Palumbo et al., “Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation”, Journal of Cell Biology, 2004, vol. 164, No. 2, pp. 441-449, 9 pages. [cited by applicant]
Palumbo et al., “High mobility group box 1 protein, a cue for stem cell recruitment”, Biochemical Pharmacology, 2004, vol. 68, pp. 1165-1170, 6 pages. [cited by applicant]
Pandya et al., “Angiogenesis—a new target for future therapy”, Vascular Pharmacology, 2006, vol. 44, pp. 265-274, 10 pages. [cited by applicant]
Pankov et al., “Fibronectin at a glance”, Journal of Cell Science, 2002, vol. 115, pp. 3861-3863, 3 pages. [cited by applicant]
Park et al., “Involvement of Toll-like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein”, Journal of Biological Chemistry, 2004, vol. 279, No. 9, pp. 7370-7377, 8 pages. [cited by applicant]
Pittenger et al., “Multilineage Potential of Adult Human Mesenchymal Stem Cells”, Science, 1999, vol. 284, pp. 143-147; 6 pages. [cited by applicant]
Popovic et al., “Increased Expression of the Novel Proinflammatory Cytokine High Mobility Group Box Chromosomal Protein 1 in Skin Lesions of Patients With Lupus Erythematosus”, Arthritis & Rheumatism, 2005, vol. 52, No.… [cited by applicant]
Raucci et al., “The Janus face of HMGB1 in heart disease: a necessary update”, Cellular and Molecular Life Sciences, 2019, vol. 76, pp. 211-229, 19 pages. [cited by applicant]